Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China

Icosapent ethyl therapy for very high triglyceride levels: a 12-week, multi-center, placebo-controlled, randomized, double-blinded, phase III clinical trial in China

Abstract Objectives Eicosapentaenoic acid in its ethyl ester form is the single active component of icosapent ethyl (IPE). This study was a phase III, multi-center trial assessing the safety and efficiency of IPE for treating very high triglyceride (TG) in a Chinese cohort. Methods Patients having T...

Full description

Bibliographic Details
Main Authors: Zhen Wang, Xin Zhang, Yanling Qu, Shuyang Zhang, Yundai Chen, Xiaoping Chen, Xin Qi, Peijing Liu, Shuqin Liu, Shan Jiang, Ronghai Man, Liping He, Ling Wu, Zhanquan Li, Yijun Shang, Zhaohui Qiu, Feng Liu, Chenhong Xu, Chunlin Lai, Junbo Ge
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Lipids in Health and Disease
Subjects:
Icosapent ethyl
Hypertriglyceridemia
Triglyceride
Low-density lipoprotein cholesterol
Online Access:https://doi.org/10.1186/s12944-023-01838-8

Internet

https://doi.org/10.1186/s12944-023-01838-8

Similar Items